Pharma ‘product-hopping’ bill gets nod from House panel

Legislation that would bar branded pharmaceutical companies from engaging in tactics to delay generic competition got the greenlight from a House panel....

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:

FTCWatch is delivered in the following formats: via email alert and online at